Study details
Enrolling now
Cardiovascular Disease Risk in Women With Endometriosis
Yale University
NCT IDNCT03746535ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
40
Study length
about 4.5 years
Ages
18–45
Sex
Female only
Locations
1 site in CT
What this study is about
Researchers are testing a treatment called Elagolix to see if it affects the risk of cardiovascular disease in women with endometriosis. The trial will last for 1644 days and involve approximately 40 adult female participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Elagolix
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
elagolix
Drug routes
oral (Oral Tablet)
Body systems
Reproductive Health